FDA Approves Gilead's Long-Acting HIV Treatment for Bi-Monthly Dosing

The U.S. Food and Drug Administration (FDA) has granted approval to lenacapavir (Sunlenca), Gilead Sciences' first-in-class capsid inhibitor, for bi-monthly treatment of HIV-1 infection in heavily treatment-experienced adults. The approval, announced on December 22, 2023, marks a significant advancement in HIV treatment, offering a novel twice-per-year dosing option for patients with limited treatment alternatives.

Breakthrough Long-Acting Treatment Option

Lenacapavir represents the first HIV-1 capsid inhibitor and introduces an innovative mechanism of action in the fight against HIV. The drug works by interfering with multiple stages of the viral lifecycle, offering a new approach for patients who have developed resistance to other antiretroviral therapies.

IntelligenceRegulatory Impact▾

FDA are the agencies to watch. Regulatory relevance reads medium for hiv/aids, with lenacapavir most exposed to upcoming decisions. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Clinical Evidence Supporting Approval

The FDA's decision was based on data from the pivotal CAPELLA trial (NCT04150068), which demonstrated significant efficacy in heavily treatment-experienced people living with multi-drug resistant HIV-1. At week 52, 83% of participants (n=36) receiving lenacapavir in combination with an optimized background regimen achieved viral suppression (HIV-1 RNA <50 copies/mL).

Key efficacy data included:

• Viral load reduction: -1.94 log10 copies/mL (p<0.0001)
• CD4+ count increase: median 81 cells/µL
• Treatment response rate: 81% at 26 weeks

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Safety Profile and Administration

The most common adverse reactions (≥3%) included injection site reactions (63%), nausea (4%), and fatigue (3%). The bi-monthly dosing schedule begins with oral loading doses on days 1 and 2, followed by subcutaneous injections on day 8 and every 26 weeks thereafter.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance low. Expect implications for hiv/aids pricing, access, and launch sequencing.

Market Impact and Access

Gilead Sciences plans to launch lenacapavir in January 2024, with a wholesale acquisition cost of $42,250 per year. The company has announced comprehensive patient support programs to help ensure access to the medication.

IntelligenceStrategic Takeaways▾

Gilead's long-acting HIV treatment has received FDA approval for bi-monthly dosing, providing patients with a more convenient and effective management option.

Expert Commentary

"The approval of lenacapavir represents a significant innovation in HIV treatment," said Dr. Deborah Birnkrant, director of the Division of Antivirals in the FDA's Center for Drug Evaluation and Research. "Its unique mechanism of action and twice-yearly dosing schedule could be transformative for patients with limited treatment options."

Frequently Asked Questions

References

1. U.S. Food and Drug Administration. FDA approval. Accessed 2026-03-31.

IntelligenceEvidence Quality▾

Claims are grounded in the cited primary and secondary sources, with editorial review applied before publication.

Related profiles

• lenacapavir

Related coverage

• FDA approves Keytruda for adjuvant NSCLC treatment, expanding Merck’s lung cancer label
• FDA approves Merck’s Keytruda for adjuvant NSCLC treatment
• Lenacapavir PrEP shows high HIV-prevention efficacy in Gilead’s Phase 3 trials